US Stock MarketDetailed Quotes

ACRS Aclaris Therapeutics

Watchlist
  • 2.085
  • +0.025+1.21%
Trading Feb 26 10:50 ET
223.13MMarket Cap-4.01P/E (TTM)

Aclaris Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Aclaris Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 2.582M--
--2024/Q4-- / 7.041M--
--2024/Q34.346M / 11.849M--
--2024/Q22.766M / 1.817M--
May 7, 20242024/Q12.398M / 1.929M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 2.582M--
--2024/Q4-- / 7.041M--
--2024/Q34.346M / 11.849M--
--2024/Q22.766M / 1.817M--
May 7, 20242024/Q12.398M / 1.929M--

Unlock Free Earnings Estimates

Aclaris Therapeutics Earnings Reports

  • Aclaris Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 6, 2024 16:34 ET

  • Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

    Nov 6, 2024 07:22 ET

  • Aclaris Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 7, 2024 22:20 ET

  • Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

    Aug 7, 2024 07:21 ET

    • Read more

    Trending Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Lantheus
    LNTH
    +18.27%
    Workday
    WDAY
    +7.06%
    Hutchmed (China)
    HCM
    +7.12%
    DexCom
    DXCM
    +1.67%
    YETI Holdings
    YETI
    +1.04%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Feb 19, 2025

    Strong Buy

    • Buy

      75.00%

    • Hold

      25.00%

    • Sell

      0.00%

    Price Target

    No Data